Bayer Appoints Habib Dable to Lead U.S. Pharmaceuticals Business

WHIPPANY, N.J., Oct. 1, 2015 /PRNewswire/ -- Bayer today announced the appointment of Habib Dable as president of Bayer HealthCare Pharmaceuticals, the U.S.-based division of the global company's pharmaceutical business. Dable will report to Philip Blake, who will now assume the role of head of region Americas for Bayer HealthCare Pharmaceuticals and continue leading U.S. corporate functions as senior Bayer representative (SBR) in the United States, a position he has held since 2012.

"Habib Dable is a highly respected leader at Bayer, and I'm thrilled to have someone with such a wealth of experience step in to lead the company's largest pharmaceuticals market worldwide," said Blake. "Having spent more than two decades at Bayer in a range of key roles with increasing management responsibility, Habib will be a critical asset as we look to build on our positive momentum in the U.S. to create long-term growth."

Habib Dable, president of Bayer HealthCare Pharmaceuticals in the U.S.

Habib Dable, president of Bayer HealthCare Pharmaceuticals in the U.S.
Previously, Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, a role he held since 2013 and in which was responsible for overseeing four therapeutic areas for the company – hematology, oncology, ophthalmology, and neurology. He began his career at Bayer in 1994 as a sales representative and moved on to hold a number of senior roles in Canada, Japan and the U.S., focusing on strategic planning, sales management, and global product marketing including successfully leading global product launches.

Dable earned a Masters of Business Administration from the University of New Brunswick in Canada, where he also completed his undergraduate study. He is married with two children, and resides in New Jersey.

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for general medicine, hematology, neurology, oncology and women's healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Bayer Corporation
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which is to be floated on the stock market as Covestro by mid-2016 at the latest. For more information, go to

Social Media Channels:

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Photo -
Logo -


Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.